What is Benitec Biopharma Operating Cash Flow per Share?
Benitec Biopharma's operating cash flow per share for the
three
months ended in Dec. 2023 was $-2.08.
Benitec Biopharma's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-9.14.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -20.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Benitec Biopharma's Operating Cash Flow per Share or its related term are showing as below:
BNTC'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -20.5 Med: 26.15 Max: 50.2
Current: -20.5
During the past 11 years, Benitec Biopharma's highest 3-Year average Operating Cash Flow per Share Growth Rate was 50.20% per year. The lowest was -20.50% per year. And the median was 26.15% per year.
BNTC's 3-Year OCF Growth Rate is ranked worse than 75.34% of 1241
companies
in the Biotechnology industry
Industry Median: 3.7
vs BNTC: -20.50
Benitec Biopharma Operating Cash Flow per Share Historical Data
The historical data trend for Benitec Biopharma's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Benitec Biopharma Operating Cash Flow per Share Chart
Competitive Comparison of Benitec Biopharma's Operating Cash Flow per Share
For the Biotechnology subindustry, Benitec Biopharma's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Benitec Biopharma's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Benitec Biopharma's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Benitec Biopharma's Price-to-Operating-Cash-Flow falls into.
Benitec Biopharma Operating Cash Flow per Share Calculation
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
Benitec Biopharma's Operating Cash Flow per Share for the fiscal year that ended in Jun. 2023 is calculated as
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.14
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Benitec Biopharma Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of Benitec Biopharma's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Benitec Biopharma (Benitec Biopharma) Business Description
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BNTC has been successfully added to your 